Optellum, AI Lung Cancer Diagnosis Innovator, Secures $14M Series A Funding to Accelerate Expansion
OXFORD, England and HOUSTON, Sept. 27, 2022 /PRNewswire/ -- Optellum, an Oxford-based medtech company that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round. The investment will enable Optellum to scale its base, operations, and commercial launches in the UK and USA; accelerate research and development; and expand its platform into personalized therapy decisions by integrating imaging data with molecular data, robotics, and liquid biopsies.
- Lung cancer is the most common type of cancer and the leading cause of cancer deaths in the world.
- Approximately 150,000 people in the United States and 1.8 million people worldwide die from lung cancer each year.
- We share Optellum's vision of making this available to every doctor in every hospital and transform the diagnosis and treatment path for lung cancer."
- Optellum also has strategic collaborations with GE Healthcare and the Lung Cancer Initiative at Johnson & Johnson to accelerate clinical deployments and continue the advancement of the platform.